摘要
目的探讨布地奈德福莫特罗联合苏黄止咳胶囊治疗咳嗽变异性哮喘的疗效及对嗜酸性粒细胞(EOS)、呼出气一氧化氮(FENO)的影响。方法将医院2015年10月至2017年8月收治的128例患者按随机数字表法分为观察组和对照组,各64例。对照组患者给予布地奈德福莫特罗干粉吸入剂,1吸/次,2次/日。观察组患者在对照组治疗基础上加用苏黄止咳胶囊,1.35 g/次,3次/日。两组均治疗3周。结果观察组总有效率为96.88%,明显高于对照组的79.69%(χ2=9.704,P<0.01);治疗后,观察组患者的第1秒用力呼气容积(FEV1)、第1秒用力呼气量与用力肺活量比值(FEV1%)均明显高于对照组(P<0.01),咳嗽症状消失时间明显短于对照组(P<0.01),中医证候总积分、视觉模拟评分(VAS)及EOS和FENO水平均明显低于对照组(P<0.01);两组不良反应发生率无明显差异(P>0.05)。结论布地奈德福莫特罗联合苏黄止咳胶囊治疗咳嗽变异性哮喘疗效显著,可明显改善EOS,FENO水平和肺功能,安全性较高,值得推广。
Objective To investigate the clinical effect of budesonide formoterol combined with Suhuang Zhike Capsules in the treatment of cough variant asthma and its effect on eosinophil(EOS)and fractional exhaled nitric oxide(FENO).Methods Totally 128 patients with cough variant asthmaa dmitted to our hospital from October 2015 to August 2017 were randomly divided into the observation group and the control group,64 cases in each group.The control group was given Budesonide Formoterol Powder for Inhalation,1 suc-tion/time,2 times/d,on this basis,the observation group was given Suhuang Zhike Capsules,1.35g/time,3times/d.The two weeks were treated for 3 weeks.Results The total effective rate of the observation group was 96.88%,which was significantly higher than 79.69%of the control group(χ2=9.704,P<0.01).After treatment,the FEV1 and FEV 1%in the observation group were significantly higher than those in the control group(P<0.01),the time of cough symptoms disappeared in the observation group was significantly shorter than that in the control group(P<0.01),the total score of TCM syndrome,the VAS score and the levels of EOS and FENO in the observation group were significantly lower than those in the control group(P<0.01).The incidence of adverse reactions of the two groups had no significant difference(P>0.05).Conclusion Budesonide formoterol combined with Suhuang Zhike Capsules in the lung of cough variant asthma has significant curative effect and high safety,it can significantly improve the EOS,FENO and pulmonary function of the patients,which is worthy of promotion.
作者
包竑弘
肖磊
马丽敏
BAO HonHong;XIAO Lei;MA LiMin(Zhangjiagang traditional Chinese medicine hospital,Jiangsu,Zhangjiagang 215600)
出处
《中国药业》
CAS
2018年第6期78-80,共3页
China Pharmaceuticals
